Could Serum TSH Levels Predict Malignancy in Euthyroid Patients Affected by Thyroid Nodules with Indeterminate Cytology?
Journal
International journal of endocrinology
ISSN: 1687-8337
Titre abrégé: Int J Endocrinol
Pays: Egypt
ID NLM: 101516376
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
05
2019
revised:
09
09
2019
accepted:
30
03
2020
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
8
5
2020
Statut:
epublish
Résumé
Serum TSH levels in the upper-normal range were reported to be associated with increased risk of thyroid malignancy. However, measurement of TSH levels is currently not recommended for assessing the risk of malignancy in patients with newly diagnosed thyroid nodules. To evaluate a possible relationship between the serum levels of TSH and the histological outcome of patients undergoing thyroidectomy for thyroid nodules with indeterminate cytology. We collected the clinical data of all patients who had performed ultrasound-guided FNA of thyroid nodules with cytological diagnosis of indeterminate lesions (TIR3A and TIR3B) and serum TSH levels within the normal range. All patients had been submitted to thyroid surgery (hemi or thyroidectomy, as appropriate), and histological diagnosis had been performed. A histological diagnosis of thyroid malignancy was rendered in 74/378 (19.6%) nodules. Patients with histologically proven thyroid malignancy were characterized by higher serum levels of TSH as compared to patients with histologically proven benign nodules (3.03 ± 1.16 vs. 2.37 ± 1.19 mIU/L, TSH levels in the upper-normal range are associated with an increased risk of thyroid malignancy in patients affected by thyroid nodules with indeterminate cytology at FNA. The measurement of serum TSH levels represents an easily performed additional tool for decision-making in patients with indeterminate cytological findings.
Sections du résumé
BACKGROUND
BACKGROUND
Serum TSH levels in the upper-normal range were reported to be associated with increased risk of thyroid malignancy. However, measurement of TSH levels is currently not recommended for assessing the risk of malignancy in patients with newly diagnosed thyroid nodules.
OBJECTIVE
OBJECTIVE
To evaluate a possible relationship between the serum levels of TSH and the histological outcome of patients undergoing thyroidectomy for thyroid nodules with indeterminate cytology.
MATERIALS AND METHODS
METHODS
We collected the clinical data of all patients who had performed ultrasound-guided FNA of thyroid nodules with cytological diagnosis of indeterminate lesions (TIR3A and TIR3B) and serum TSH levels within the normal range. All patients had been submitted to thyroid surgery (hemi or thyroidectomy, as appropriate), and histological diagnosis had been performed.
RESULTS
RESULTS
A histological diagnosis of thyroid malignancy was rendered in 74/378 (19.6%) nodules. Patients with histologically proven thyroid malignancy were characterized by higher serum levels of TSH as compared to patients with histologically proven benign nodules (3.03 ± 1.16 vs. 2.37 ± 1.19 mIU/L,
CONCLUSIONS
CONCLUSIONS
TSH levels in the upper-normal range are associated with an increased risk of thyroid malignancy in patients affected by thyroid nodules with indeterminate cytology at FNA. The measurement of serum TSH levels represents an easily performed additional tool for decision-making in patients with indeterminate cytological findings.
Identifiants
pubmed: 32377187
doi: 10.1155/2020/7543930
pmc: PMC7191401
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7543930Informations de copyright
Copyright © 2020 Carlo Cappelli et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Références
Diabetes Care. 2009 Sep;32(9):1589-90
pubmed: 19502536
Cytopathology. 2017 Dec;28(6):503-508
pubmed: 28913847
J Cancer Res Clin Oncol. 2008 Sep;134(9):953-60
pubmed: 18327610
Med Princ Pract. 2018;27(3):272-277
pubmed: 29514150
Thyroid. 2008 Sep;18(9):943-52
pubmed: 18788918
Am J Surg. 2010 Mar;199(3):294-7; discussion 298
pubmed: 20226898
Cytopathology. 2017 Dec;28(6):475-481
pubmed: 29165888
J Clin Endocrinol Metab. 2012 Aug;97(8):2682-92
pubmed: 22622023
Best Pract Res Clin Endocrinol Metab. 2014 Aug;28(4):545-57
pubmed: 25047205
Adv Anat Pathol. 2019 Mar;26(2):114-123
pubmed: 30664001
Eur J Endocrinol. 2012 Aug;167(2):261-5
pubmed: 22645202
J Clin Endocrinol Metab. 2008 Mar;93(3):809-14
pubmed: 18160464
PLoS One. 2017 Nov 16;12(11):e0188123
pubmed: 29145466
Br J Oral Maxillofac Surg. 2017 Apr;55(3):266-269
pubmed: 27938945
Endocr Relat Cancer. 2018 Mar;25(3):R163-R177
pubmed: 29255094
N Engl J Med. 2012 Aug 23;367(8):705-15
pubmed: 22731672
N Engl J Med. 2004 Oct 21;351(17):1764-71
pubmed: 15496625
Int J Surg. 2017 May;41 Suppl 1:S60-S64
pubmed: 28506415
Endocrinol Nutr. 2015 Jan;62(1):24-8
pubmed: 25066642
Korean J Radiol. 2015 Mar-Apr;16(2):391-401
pubmed: 25741201
Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):858-863
pubmed: 30049841
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
J Clin Endocrinol Metab. 2006 Nov;91(11):4295-301
pubmed: 16868053
Eur Thyroid J. 2017 Apr;6(2):75-81
pubmed: 28589088
Mol Cell Endocrinol. 2003 Dec 31;213(1):31-45
pubmed: 15062572
Eur Thyroid J. 2017 Sep;6(5):225-237
pubmed: 29167761
Eur J Clin Invest. 2009 Aug;39(8):699-706
pubmed: 19601965
Arch Otolaryngol Head Neck Surg. 2008 Jun;134(6):581-6
pubmed: 18559722
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Endocrinol Invest. 2010 May;33(5):287-91
pubmed: 20479572
Endocr Relat Cancer. 2009 Dec;16(4):1251-60
pubmed: 19528244
Cancer. 2018 Mar 1;124(5):888-898
pubmed: 29278433